IN2014DN06734A - - Google Patents
Info
- Publication number
- IN2014DN06734A IN2014DN06734A IN6734DEN2014A IN2014DN06734A IN 2014DN06734 A IN2014DN06734 A IN 2014DN06734A IN 6734DEN2014 A IN6734DEN2014 A IN 6734DEN2014A IN 2014DN06734 A IN2014DN06734 A IN 2014DN06734A
- Authority
- IN
- India
- Prior art keywords
- compositions
- pharmaceutically acceptable
- type
- replacement surgery
- particles comprise
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts polymorphs solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN6734DEN2014 IN2014DN06734A (en) | 2012-02-21 | 2013-02-21 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN461MU2012 | 2012-02-21 | ||
PCT/EP2013/053426 WO2013124340A1 (en) | 2012-02-21 | 2013-02-21 | Oral pharmaceutical compositions of dabigatran etexilate |
IN6734DEN2014 IN2014DN06734A (en) | 2012-02-21 | 2013-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN06734A true IN2014DN06734A (en) | 2015-05-22 |
Family
ID=47739283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN6734DEN2014 IN2014DN06734A (en) | 2012-02-21 | 2013-02-21 |
Country Status (27)
Country | Link |
---|---|
US (3) | US11013729B2 (en) |
EP (2) | EP2817000B1 (en) |
JP (1) | JP6215239B2 (en) |
KR (1) | KR102090242B1 (en) |
CN (2) | CN110123774A (en) |
AU (1) | AU2013224146B2 (en) |
BR (1) | BR112014020474B1 (en) |
CA (1) | CA2864423C (en) |
CY (1) | CY1124678T1 (en) |
DK (1) | DK2817000T3 (en) |
ES (1) | ES2895918T3 (en) |
HK (1) | HK1203832A1 (en) |
HR (1) | HRP20211606T1 (en) |
HU (1) | HUE056194T2 (en) |
IL (1) | IL234032B (en) |
IN (1) | IN2014DN06734A (en) |
JO (1) | JO3616B1 (en) |
LT (1) | LT2817000T (en) |
MX (1) | MX368868B (en) |
NZ (1) | NZ628301A (en) |
PL (1) | PL2817000T3 (en) |
PT (1) | PT2817000T (en) |
RS (1) | RS62566B1 (en) |
RU (1) | RU2633482C2 (en) |
SI (1) | SI2817000T1 (en) |
WO (1) | WO2013124340A1 (en) |
ZA (1) | ZA201405855B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2817000B1 (en) | 2012-02-21 | 2021-08-04 | Towa Pharmaceutical Europe, S.L. | Oral pharmaceutical compositions of dabigatran etexilate |
CN104224754A (en) * | 2013-06-21 | 2014-12-24 | 四川海思科制药有限公司 | Dabigatran etexilate medicine composition and preparation method thereof |
CN104414995A (en) * | 2013-09-04 | 2015-03-18 | 天津汉瑞药业有限公司 | Pharmaceutical composition of dabigatran etexilate mesylate |
EP2853260A1 (en) * | 2013-09-27 | 2015-04-01 | ratiopharm GmbH | Pharmaceutical preparation comprising dabigatran etexilate bismesylate |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
CN104784147B (en) * | 2014-01-20 | 2018-01-23 | 成都苑东生物制药股份有限公司 | A kind of dabigatran etexilate methanesulfonate pharmaceutical capsules composition and preparation method thereof |
CN104994856A (en) * | 2014-01-30 | 2015-10-21 | 杭州领业医药科技有限公司 | Administered formulation of Dabigatran etexilate and salt thereof and preparation method thereof |
CN104922092A (en) * | 2014-03-19 | 2015-09-23 | 陕西天森药物研究开发有限公司 | Pharmaceutical composition of dabigatran prepared by wrapping method, salts and hydrates thereof |
IN2014MU01042A (en) | 2014-03-26 | 2015-10-02 | Cadila Healthcare Ltd | |
CN104095830A (en) * | 2014-05-22 | 2014-10-15 | 万特制药(海南)有限公司 | Preparation method for mesylate dabigatran capsule |
CN104825422B (en) * | 2014-09-29 | 2017-12-12 | 普济生物科技(台州)有限公司 | Pharmaceutical composition containing dabigatran etcxilate mesylate and preparation method thereof |
CN105560206A (en) * | 2014-10-13 | 2016-05-11 | 重庆圣华曦药业股份有限公司 | Preparation of Pradaxa capsule |
CA3001495C (en) * | 2014-11-03 | 2021-07-20 | Solipharma Llc | Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof |
WO2016107605A1 (en) * | 2014-12-31 | 2016-07-07 | 昆明积大制药股份有限公司 | Pharmaceutical composition and preparation method therefor |
WO2017103945A1 (en) * | 2015-12-15 | 2017-06-22 | Strides Shasun Limited | Pharmaceutical compositions |
CN106890148A (en) * | 2015-12-21 | 2017-06-27 | 青岛黄海制药有限责任公司 | A kind of dabigatran etcxilate tablet and its preparation |
WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
JP2018184375A (en) * | 2017-04-27 | 2018-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tablet comprising dabigatran etexilate or pharmaceutically acceptable salt thereof and method for producing the same |
WO2019004980A2 (en) * | 2017-05-10 | 2019-01-03 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Solid oral pharmaceutical compositions of dabigatran etexilate |
TR201706848A2 (en) * | 2017-05-10 | 2018-11-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING DABIGATRAN ETEXCLATE |
TR201722353A2 (en) * | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | PHARMACEUTICAL FORMULATION FOR ORAL APPLICATION WITH DABIGATRAN SKIRT |
TR201722323A2 (en) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Oral pharmaceutical compositions of dabigatran |
TR201722630A2 (en) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | |
CN110339193B (en) | 2018-04-04 | 2022-04-29 | 上海汉都医药科技有限公司 | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof |
EP3787624A4 (en) | 2018-05-04 | 2022-03-30 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Capsule-in-capsule compositions of dabigatran etexilate |
TR201905308A2 (en) * | 2019-04-09 | 2020-10-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A CAPSULE FORMULATION OF DABIGATRAN ETEXILATE |
CN113577067B (en) * | 2021-06-03 | 2023-08-15 | 北京福元医药股份有限公司 | Dabigatran etexilate mesylate pharmaceutical preparation |
CN115006363A (en) * | 2022-06-23 | 2022-09-06 | 上海信谊万象药业股份有限公司 | Oyster calcium carbonate chewable tablets and preparation method thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
JPH04103525A (en) | 1990-08-22 | 1992-04-06 | Sanwa Kagaku Kenkyusho Co Ltd | Production of sustainable pharmaceutical preparation for poorly water-soluble medicine |
PE121699A1 (en) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN |
TW550090B (en) | 1997-05-09 | 2003-09-01 | Sage Pharmaceuticals Inc | Stable oral pharmaceutical dosage forms for acid-unstable drug |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
DE60236850D1 (en) | 2001-02-15 | 2010-08-12 | Mitsubishi Tanabe Pharma Corp | TABLETS FALLING FAST IN THE MOUTHHOUSE |
DE10209985A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral pharmaceutical composition comprises the thrombin inhibitor ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate and an organic acid |
JP3866715B2 (en) * | 2002-03-07 | 2007-01-10 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 3-[(2-{[4- (Hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-benzimidazol-5-carbonyl) -pyridin-2-yl-amino] -Oral application dosage form of ethyl propionate and its salts |
US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DE10337697A1 (en) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts |
DE10339862A1 (en) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New crystalline forms of ethyl 3-(N-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-N-(2-pyridyl)amino)propionate methanesulfonate used for post-operative prophylaxis of deep vein thrombosis |
AU2004289222B2 (en) | 2003-11-04 | 2010-01-21 | Supernus Pharmaceuticals Inc. | Compositions of quaternary ammonium containing bioavailability enhancers |
CN1976903A (en) | 2004-06-02 | 2007-06-06 | 法莫西克立克斯公司 | Factor VIIa inhibitor |
KR101257343B1 (en) | 2004-07-30 | 2013-04-23 | 메틸진 인코포레이티드 | Inhibitors of vegf receptor and hgf receptor signaling |
AU2006337643A1 (en) | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Dipyridamole extended-release formulations and process for preparing same |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
EP2271317B1 (en) | 2008-03-28 | 2017-04-19 | Boehringer Ingelheim International GmbH | Method for manufacturing acid pellets |
CN101980697A (en) * | 2008-03-28 | 2011-02-23 | 贝林格尔.英格海姆国际有限公司 | Process for preparing orally administered dabigatran formulations |
NZ589746A (en) * | 2008-07-14 | 2012-10-26 | Boehringer Ingelheim Int | Method for manufacturing medicinal compounds containing dabigatran |
EP2588090B2 (en) * | 2010-07-01 | 2023-11-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts |
EA201391758A1 (en) | 2011-05-24 | 2014-06-30 | Тева Фармасьютикал Индастриз Лтд. | SPRONGED HEART FOR PHARMACEUTICAL COMPOSITION CONTAINING ORGANIC ACIDS |
EP2817000B1 (en) | 2012-02-21 | 2021-08-04 | Towa Pharmaceutical Europe, S.L. | Oral pharmaceutical compositions of dabigatran etexilate |
CN102793699B (en) | 2012-08-06 | 2014-06-04 | 严轶东 | Medicinal composition containing dabigatran etexilate |
-
2013
- 2013-02-21 EP EP13704974.8A patent/EP2817000B1/en active Active
- 2013-02-21 PL PL13704974T patent/PL2817000T3/en unknown
- 2013-02-21 HR HRP20211606TT patent/HRP20211606T1/en unknown
- 2013-02-21 RU RU2014138036A patent/RU2633482C2/en active
- 2013-02-21 KR KR1020147026330A patent/KR102090242B1/en active IP Right Grant
- 2013-02-21 NZ NZ628301A patent/NZ628301A/en unknown
- 2013-02-21 ES ES13704974T patent/ES2895918T3/en active Active
- 2013-02-21 IN IN6734DEN2014 patent/IN2014DN06734A/en unknown
- 2013-02-21 DK DK13704974.8T patent/DK2817000T3/en active
- 2013-02-21 BR BR112014020474-8A patent/BR112014020474B1/en active IP Right Grant
- 2013-02-21 SI SI201331940T patent/SI2817000T1/en unknown
- 2013-02-21 CA CA2864423A patent/CA2864423C/en active Active
- 2013-02-21 CN CN201910336600.8A patent/CN110123774A/en active Pending
- 2013-02-21 US US14/379,613 patent/US11013729B2/en active Active
- 2013-02-21 HU HUE13704974A patent/HUE056194T2/en unknown
- 2013-02-21 LT LTEPPCT/EP2013/053426T patent/LT2817000T/en unknown
- 2013-02-21 JP JP2014558094A patent/JP6215239B2/en active Active
- 2013-02-21 EP EP21164447.1A patent/EP3858337A3/en active Pending
- 2013-02-21 WO PCT/EP2013/053426 patent/WO2013124340A1/en active Application Filing
- 2013-02-21 PT PT137049748T patent/PT2817000T/en unknown
- 2013-02-21 JO JOP/2013/0057A patent/JO3616B1/en active
- 2013-02-21 AU AU2013224146A patent/AU2013224146B2/en active Active
- 2013-02-21 MX MX2014010040A patent/MX368868B/en active IP Right Grant
- 2013-02-21 RS RS20211239A patent/RS62566B1/en unknown
- 2013-02-21 CN CN201380010066.2A patent/CN104114158A/en active Pending
-
2014
- 2014-08-10 IL IL234032A patent/IL234032B/en active IP Right Grant
- 2014-08-11 ZA ZA2014/05855A patent/ZA201405855B/en unknown
-
2015
- 2015-05-12 HK HK15104458.0A patent/HK1203832A1/en unknown
-
2021
- 2021-04-27 US US17/241,793 patent/US11752142B2/en active Active
- 2021-10-29 CY CY20211100933T patent/CY1124678T1/en unknown
-
2023
- 2023-07-21 US US18/356,642 patent/US20240139168A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN06734A (en) | ||
CO6640207A2 (en) | Apixaban formulations | |
MY190835A (en) | Bicyclic heterrocyclic derivatives as bromodomain inhibitors | |
MX2015002378A (en) | Anxiolytic composition, formulation and method of use. | |
MX2015012414A (en) | Salt of omecamtiv mecarbil and process for preparing salt. | |
MX2017004950A (en) | Compositions and methods for treating insomnia. | |
IN2014MU01042A (en) | ||
WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
IN2014MN02245A (en) | ||
IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n-methylbenzofuran-3-carboxamide compounds, pharmaceutically acceptable salts thereof and pharmaceutical composition comprising them | |
WO2012113850A3 (en) | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR | |
MD4563C1 (en) | Co-micronisation product comprising ulipristal acetate | |
MX2016013589A (en) | Compositions comprising osteopontin derivatives for the inhibition of hair growth. | |
AR086800A1 (en) | TOPICA OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB | |
CR20140540A (en) | NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL | |
EP2722042A4 (en) | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | |
PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
TN2017000234A1 (en) | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors | |
TN2014000060A1 (en) | Benzothiazolone compound | |
IN2014CN02680A (en) | ||
PH12018502111A1 (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
MX2016016039A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof. | |
PH12014501352A1 (en) | Non-enteric pharmaceutical composition comprising crofelemer | |
WO2012134187A3 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
MX2021000769A (en) | Pharmaceutical composition containing clomipramine and preparation method therefor. |